A Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP of the European Pharmacopoeia monograph is often referred to as a Levonelle, D-Norgestrel, Levonova, Levonorgestrel Certificate of Suitability (COS). The purpose of a Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Levonelle, D-Norgestrel, Levonova, Levonorgestrel EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Levonelle, D-Norgestrel, Levonova, Levonorgestrel to their clients by showing that a Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP has been issued for it. The manufacturer submits a Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP (COS) as part of the market authorization procedure, and it takes on the role of a Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP holder for the record. Additionally, the data presented in the Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Levonelle, D-Norgestrel, Levonova, Levonorgestrel DMF.
A Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Levonelle, D-Norgestrel, Levonova, Levonorgestrel CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Levonelle, D-Norgestrel, Levonova, Levonorgestrel suppliers with CEP (COS) on PharmaCompass.